Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2024; 15(2): 165-168
Published online Feb 24, 2024. doi: 10.5306/wjco.v15.i2.165
Circulating tumor cells as prognostic marker in pancreatic cancer
Melek Yakar, Durmuş Etiz
Melek Yakar, Department of Radiation Oncology, Osmangazi University, Eskişehir 26040, Turkey
Durmuş Etiz, Department of Radiation Oncology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir 26040, Turkey
Author contributions: Yakar M and Etiz D contributed to this paper; Yakar M designed the overall concept and outline of the manuscript; Etiz D contributed to the discussion and design of the manuscript; Yakar M and Etiz D contributed to the writing, and editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: All the authors have no commercial associations or sources of support that might pose a conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Melek Yakar, MD, Adjunct Associate Professor, Radiation Oncology, Osmangazi University, Meşelik Campus Büyükdere District Prof. Dr. Nabi AVCI Boulevard No. 4 26040 Odunpazarı, Eskişehir 26040, Turkey. myakar@ogu.edu.tr
Received: December 3, 2023
Peer-review started: December 3, 2023
First decision: December 7, 2023
Revised: December 16, 2023
Accepted: January 9, 2024
Article in press: January 9, 2024
Published online: February 24, 2024
Processing time: 78 Days and 21.3 Hours
Core Tip

Core Tip: Pancreatic cancer is a cancer that is usually diagnosed at an advanced stage due to its late onset of symptoms and rapid progression, and therefore has a high mortality rate despite intensive treatments. Detecting patients at an earlier stage is important in terms of cure rates. Predicting occult metastases in radiologically resectable cases will prevent unnecessary surgery. Additionally, if the patient's prognosis can be predicted, different treatment strategies and even personalized treatments may come to the fore. Currently, there is no reliable biomarker for diagnosis, staging or prognosis prediction in pancreatic cancer. Circulating tumor cells are promising in this respect.